000 06547cam a2200469Ia 4500
001 94929
003 ES-MaUEC
005 20230102112639.0
006 m o d
007 cr cnu---unuuu
008 161126t20162017sz o 000 0 eng d
020 _a3319336797
_q(electronic bk.)
020 _a9783319336794
_q(electronic bk.)
020 _z9783319336770
_q(print)
035 _a(OCoLC)964403216
040 _aEBLCP
_cEBLCP
_dGW5XE
_dN$T
_dOCLCF
_dYDX
_dAZU
_dUAB
_dOCLCQ
_dIOG
_dMERER
_dESU
_dZ5A
_dOCLCQ
_dJBG
_dIAD
_dICW
_dICN
_dOHI
_dOTZ
_dU3W
_dES-MaUEC
_bspa
050 4 _aRC281.C4
_b2017 EB
245 0 0 _aCancer in adolescents and young adults
_cArchie Bleyer [and others], editors.
250 _a2nd ed.
264 1 _aCham
_bSpringer International Publishing
300 _a1 recurso en línea (830 páginas)
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
490 0 _aPediatric Oncology
505 0 _aForeword; Foreword; Foreword; Foreword; Preface; The Evolution of Adolescent Oncology in the United States; Background; A Decade of Experience: 1978-1989; Scaling Up: 1992-The Present; References; Contents; 1: Adolescent and Young Adult Oncology: Historical and Global Perspectives; References; 2: Cancer Incidence, Survival, and Mortality Among Adolescents and Young Adults; 2.1 Introduction; 2.2 Sources of Information and Modes of Analysis: Incidence, Survival, and Mortality; 2.2.1 Age; 2.3 Data Sources and Analyses; 2.3.1 Incidence; 2.3.2 Survival; 2.3.3 Mortality.
505 8 _a2.4 Global, Regional, and National Perspectives; 2.4.1 Incidence; 2.4.1.1 Cancer Incidence Worldwide; 2.4.1.2 Worldwide Geographic Variation; 2.4.1.3 Overall Incidence by Single Years of Age (US SEER); 2.4.1.4 Individual Cancer Incidence by 5-Year Age Intervals (US SEER); 2.4.1.5 Individual Cancer Incidence by Age Group, Site, and Sex (US SEER); 2.4.1.6 Incidence Trends by Site (US SEER); 2.4.2 Survival; 2.4.2.1 Site Distribution and Survival (Europe, US SEER, Japan); 2.4.2.2 Survival for AYAs Compared to Children (Age <15 Years).
505 8 _a2.4.2.3 Survival for AYAs Compared to Older Adults (Age 40-69); 2.4.2.4 Survival Trends; 2.4.3 Mortality; 2.4.3.1 Cancer Mortality Worldwide; 2.4.3.2 Death Rates and Trends by Site; 2.5 Etiology, Biology, Trends, and International Progress; Appendix; References; 3: The Biology of AYA Cancers; 3.1 Introduction; 3.2 Old Questions and New Technologies; 3.3 Four AYA Cancers with Biologic Distinction; 3.3.1 Colorectal Cancer; 3.3.2 Acute Lymphoblastic Leukemia; 3.3.3 Breast Cancer; 3.3.4 Melanoma; 3.3.5 Sarcoma; 3.4 Summary; References; 4: Non-Hodgkin Lymphoma; 4.1 Introduction.
505 8 _a4.2 Epidemiology; 4.2.1 Age-Specific Incidence; 4.2.2 Incidence of Histologic Types; 4.3 Etiology/Risk Factors; 4.4 Histology/Cytogenetics; 4.5 Clinical Features; 4.6 Initial Workup and Staging; 4.7 B-Cell Non-Hodgkin Lymphoma; 4.7.1 Burkitt Lymphoma; 4.7.2 Diffuse Large B-Cell Lymphoma; 4.7.2.1 Primary Mediastinal B-Cell Lymphoma; 4.7.3 Anaplastic Large Cell Lymphoma; 4.7.3.1 Biology/Pathology; 4.7.3.2 Management of S-ALCL; 4.7.3.3 Management of C-ALCL; 4.7.3.4 Prognostic Factors; 4.7.3.5 Treatment of Relapses; 4.8 Lymphoblastic Lymphoma; 4.8.1 Biology/Pathology.
505 8 _a4.8.2 Treatment and Management; 4.9 Rare Non-Hodgkin Lymphomas in Adolescents and Young Adults; 4.10 Overall Survival; References; 5: Hodgkin Lymphoma; 5.1 Introduction; 5.2 Epidemiology; 5.2.1 Incidence; 5.2.1.1 Age and Gender; 5.2.1.2 Race and Ethnicity; 5.3 Etiology and Pathogenesis; 5.4 Pathology; 5.5 Presenting Features; 5.6 Diagnostic Testing; 5.6.1 Tissue Diagnosis; 5.6.2 Other Laboratory Studies; 5.6.3 Imaging Studies; 5.7 Staging and Risk Assessment; 5.7.1 Risk Strata for Treatment Determination; 5.8 Therapy; 5.8.1 General Principles.
505 8 _a5.8.2 Management of Limited-Stage Hodgkin Lymphoma.
520 3 _aThis is the second edition of the only book to be devoted exclusively to the total cancer picture in adolescents and young adults (AYA), now expanded from the age range 15-29 to that of 15-39 years. For each of the diverse spectrum of cancers encountered in the AYA group, the epidemiology, natural progression, diagnostic approaches, and treatment options are described, with special emphasis on strategies for early detection and prevention. Comparison is made with management of both younger and older patients, and model programs are presented that address common diagnostic, staging, treatment, and psychosocial shortcomings in the AYA group. Detailed attention is also paid to principles and practices of care, with consideration of psychosocial and quality of life issues, social support systems, rehabilitation, late effects, insurance, and economic aspects of health care, among other topics. The authors make compelling arguments for integrated strategies that allow young adults to benefit from the combined expertise of pediatric and adult oncologists in systems that identify both the complex disease and the social issues specific to this population. The proposed models of care include relationships with other specialties that do not specifically target this age group, i.e., infectious disease, endocrinology, pulmonary medicine, nephrology, gastroenterology, thoracic and abdominal surgery, urology, otolaryngology, and neurosurgery. New patterns of communication are advocated and endorsed as essential for productive interaction involving these specialties. References are extensive and are oriented toward users in pediatric hematology-oncology medical oncology, radiation oncology, surgical oncology, gynecologic oncology, oncology nursing, psycho-oncology, social work, epidemiology, public health and health services research. The contributing authors are from the United States, the United Kingdom, Canada, Italy, France, Israel, Switzerland and Australia, Germany, Japan and the Netherlands.
650 7 _aCáncer en adolescentes
_2embne
_0(OCoLC)fst00845578
_0
_9672833
700 1 _aBarr, Ronald D.
700 1 _aBleyer, W. Archie,
_d1943-
700 1 _aFerrari, Andrea
_c(Physician)
700 1 _aRies, Lynn A. Gloeckler.
700 1 _aWhelan, Jeremy
_c(Professor of cancer medicine)
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-33679-4
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988 _aSpringer_Medicine_2017
998 _b02/2018
_dz
_e-
_zSI
999 _c94929
_d94929
_x1